Abstract
Thirty five samples of bone marrow (BM) from 17 patients (pts) with ALL and 18 pts with AML (aged 9m–20yrs, median 7.7 yrs) were obtained. Using MTT-assay the sensitivity of LB to Ara-C, VP-16, DOX, G(GM)-CSF and their combinations was measured. LC50 was higher in pts with AML than with ALL: to Ara-C 1.94-fold (p<0.05), to VP-16 1.62-fold (p=0.2), to DOX 3.9-fold (p<0.05). Incubation with G-CSF increased the viability of ALL and AML LB-104.3% and 104.1% respectively (the viability of leukemic cells without CSF accepted as 100%). Incubation with GM-CSF decreased the viability of ALL LB (96.5%) and increased the viability of AML LB (139.1%) (p = 0.08). Combining Ara-C with G- or GM-CSF resulted in equal or increased LC50 (compared with LC50 of Ara-C alone) in 100% cases of AML. For ALL: LC50 of “Ara-C+G-CSF” was equal or increased in 63.6% cases; LC50 of “Ara-C+GM-CSF”- in 62.5%. For VP-16 and DOX all pts (ALL,AML) except two had equal or increased LC50 of “CH+CSF” (compared with LC50 of CH alone). These data show: 1) AML LB were less sensitive to the investigated CH than ALL LB. 2) The LC50 of “CH+CSF” was equal or increased compared to the LC50 of CH for the absolute majority of cases with VP-16 and DOX. The same results were obtained with AML and in about 60% cases of ALL. The effect of the increasing of cytototoxity of CH in presence of CSF probably exists mostly at higher concentrations of CH than those that can be achieved in clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Koistinen P., Wang C., Yang GS, et al. OCI/AML-4 an acute myeloblastic leukemia cell line: Regulation and response to cytosine arabinoside. Leukemia 1991, 5, 704–711.
Tafuri A., Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990, 4, 826–834.
Metelitsa L., Shmelev V., Shvedova E., Popov A., Mentkevich G. 25 Effects of cytokines and their combinations with Ara-C on short term culture of tumor cells from children with acute leukemia by the MTT-assay. In Pieters R., Kaspers G.J.L., Veerman A.J.P. (eds): “Drug resistance in Leukemia and Lymphoma II”. Harwood academic publishers, 1997, 209–216.
Clarkson B., Strife A., Fried J., et al. Studies of cellular proliferation in human leukemia. IV. Behavior of leukemic cells in 3 adults with acute leukemia given continuous infusion of 3H-thymidine for 8 to 10 days. Cancer, 1970, 26, 1–19.
Raza A., Maheshwari Y., Preisler HD. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood, 1987, 69(6), 1647–1653.
Hirt A., Antic V., Wang E., Luthy AR., Leibundgut R., et al. Acute lymphoblastic leukaemia in children: cell proliferation without rest. Br J Haematology 1997, 96, 366–368.
Campana D., Janossy G.: Proliferatoin of normal and malignant human immature lymphoid cells. Blood, 1988, 71, 1201.
Cannistra SA, Groshek P., Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and on the myeloid blast crisis phase of chronic myelogenous leukemia. Leukemia, 1989, 3, 328–334.
Sundman-Engberg B., Tidelfelt U., Paul C. 24 In vitro studies of growth factors in combination with cytostatic drugs on human leukemia cells. In Pieters R., Kaspers G.J.L., Veerman A.J.P. (eds): “Drug resistance in Leukemia and Lymphoma II”. Harwood academic publishers, 1997, 203–208.
Hederson E.S., Lister T.A., Greaves M.F. (eds): “Leukemia. Sixth edition”, 1996.
Bhalla K., Ibrado AM, Holladay C., Bullock G. Hemopoietic growth factors (HGFs) G-CSF and Il-3 improve the antileukemic selectivity of high-dose Ara-C (HIDAC). Blood 1991, 78(Suppl 1), 425 (abstr).
Smith MA, Singer CRG, Pallister CJ, Smith JG. The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro. Br J Haematology, 1995, 90, 767–773.
Koistinen P., Wang C., Curtis JE, McCulloch EA. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemia blast cells from Ara-C toxity. Leukemia 1991, 5, 789–795.
Kaplinsky C., Lotem J., Sachs L. Protection of human myeloid leukemia cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin-3. Leukemia, 1996, 10, 460–465.
Estey E., Thall PF, Kantarjian H., et al: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous infusion high-dose Ara-C+daunorubicin: Comparison to patients treated without GM-CSF. Blood 1992, 79, 2246–2255.
Bettelheim P., Valent P., Andreeff M., Tafuri A., Haimi J., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991, 77, 700–711.
Archimbaud E., Fenaux P., Reiffers J., Cordonnier C., Leblond V., Travade P., Troussard X., et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993, 7, 372–377.
DiGiusto D., Chen S., Combs J., et al. Human fetal bone marrow early progenitors for T, B, and myeloid cells are exclusively in the population expressing high levels of CD34. Blood 1994, 84, 421
Kurtzberg J., Waldmann TA, Davey MP, et al. CD7+, CD4-, CD8-acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells. Blood 1989, 73, 381.
Serrano J., Roman J., Sanchez J., Torres A. Myeloperoxidase gene expression in acute lymphoblastic leukaemia. Br J Haematology 1997, 97, 841–843.
Matsushita K., Arama N., Ohtsubo H., Fujiwara H., et al. Granulocyte colony-stimulating factor-induced proliferation of primary adult T-cell leukemia cells. Br J Haematology 1996, 96, 715–723.
Preisler HD, Raza A., Larson R., Goldberg J., Tricot G., et al. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leuk Res 1991, 15(9), 773–780.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Litvinova, E., Gurova, K., Chimishkian, K., Mentkevich, G. (1999). Effects of CSFS and their Combinations with Chemotherapeutic Agents (CH) on Leukemic Blasts (LB) in Children (MTT-Assay). In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_65
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_65
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive